AIDX 10-Q: SEC filing
20/20 Biolabs
Filed with the SEC on · accession 0001213900-26-120727
AIDX filed a 10-Q (quarterly report) with the SEC on Nov 16, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -9.4% by the first close after the filing.
Summary of the filing
20/20 Biolabs filed its Q3 2026 Form 10-Q, reporting quarterly financial results and detailing various financing activities including preferred stock conversions, warrant issuances, and convertible note transactions.
Key details
How AIDX stock reacted
Close before
$0.20
Nov 13, 2026
First close after
-9.45%
$0.18
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for AIDX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for AIDX?
Click hereFrequently asked questions
What did AIDX file with the SEC on Nov 16, 2026?
AIDX filed a 10-Q (SEC filing). 20/20 Biolabs filed its Q3 2026 Form 10-Q, reporting quarterly financial results and detailing various financing activities including preferred stock conversions, warrant issuances, and convertible note transactions.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did AIDX stock react to this filing?
AIDX closed at $0.20 before the filing and $0.18 on Nov 16, 2026 (-9.45%).
Other AIDX SEC filings
Get alerts when AIDX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days